ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

ATNM Actinium Pharmaceuticals Inc

6.80
0.24 (3.66%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Actinium Pharmaceuticals Inc ATNM AMEX Common Stock
  Price Change Price Change % Share Price Last Trade
0.24 3.66% 6.80 08:56:02
Open Price Low Price High Price Close Price Previous Close
6.58 6.485 6.92 6.87 6.56
more quote information »

Recent News

Date Time Source Heading
18/4/202422:00PRNUSActinium Highlights Ability of Iomab-B to Overcome High-Risk..
01/4/202423:00PRNUSActinium Announces Iomab-B Phase 3 SIERRA Trial Results..
26/3/202422:18PRNUSActinium Announces Clinical Trial to Study Iomab-ACT..
11/3/202422:30PRNUSActinium Pharmaceuticals Launches Actinium-225 Focused..
26/2/202423:30PRNUSActinium Announces Iomab-B Markedly Increases Long Term..
23/2/202423:30PRNUSActinium Highlights Improved Survival with Iomab-B in TP53..
10/2/202408:30EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202416:15EDGAR2Form EFFECT - Notice of Effectiveness
03/2/202409:03EDGAR2Form S-3/A - Registration statement under Securities Act of..
02/1/202423:30PRNUSActinium Announces Acceptance of Five Abstracts for..
30/12/202309:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/12/202309:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/12/202309:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/12/202309:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/12/202309:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202300:15PRNUSActinium Announces Iomab-B Produces High Response Rates and..
11/12/202323:45PRNUSActinium's Four Presentations at ASH Highlight the Positive..
09/12/202300:00PRNUSActinium to Highlight Broad Potential of Targeted..
02/12/202309:00EDGAR2Form 8-K - Current report
10/11/202309:05EDGAR2Form DEF 14A - Other definitive proxy statements
06/11/202323:30PRNUSActinium Presents Preclinical Data at SITC Demonstrating..
03/11/202307:15PRNUSActinium Pharmaceuticals to Attend Bio-Europe Munich 2023
03/11/202300:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202300:05PRNUSActinium Announces Oral Presentation at ASH Annual Meeting..
04/10/202322:30PRNUSActinium Announces NIH Grant Extension to Advance Clinical..
27/9/202323:05PRNUSActinium Pharma Highlights Abstract Accepted for Poster..
07/9/202322:40PRNUSActinium Pharma Presents Survival Data from Extended..
31/8/202321:00PRNUSActinium Pharma Highlights Three Abstracts Accepted for..
21/8/202321:00PRNUSActinium Pharma Highlights Abstracts Accepted for Oral and..
15/8/202307:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202323:00EDGAR2Form S-3 - Registration statement under Securities Act of..
24/7/202321:00PRNUSActinium Pharma to Present at the 2nd Annual Targeted..
26/6/202321:00PRNUSSNMMI 2023 Annual Meeting Abstract of the Year Awarded to..
23/6/202322:00PRNUSActinium Pharma Highlights Six Abstracts Accepted for Oral..
16/6/202321:00PRNUSActinium Pharma to Present at the Maxim Healthcare Virtual..
14/6/202321:00PRNUSActinium Pharma to Present at the TD Cowen..
12/6/202321:00PRNUSActinium Announces Positive Pivotal Phase 3 SIERRA Trial..
07/6/202321:00PRNUSActinium Pharma Set to Join Russell 2000® and Russell 3000®..
22/5/202321:00PRNUSActinium Pharma Announces Six Abstracts Accepted for Oral..
12/5/202301:18PRNUSActinium Pharma Announces Iomab-B SIERRA Trial Results..
10/5/202321:00PRNUSActinium Pharma to Present at Guggenheim Healthcare Talks..
28/4/202322:00PRNUSActinium Highlights Successful Administration of Targeted..

Your Recent History

Delayed Upgrade Clock